Dear Editor： Growing evidence demonstrates that β2-glycoprotein Ⅰ （β2GPI） is the key target for antiphospholipid antibodies which are closely associated with thrombotic events in antiphospholipid syndrome （APS...Dear Editor： Growing evidence demonstrates that β2-glycoprotein Ⅰ （β2GPI） is the key target for antiphospholipid antibodies which are closely associated with thrombotic events in antiphospholipid syndrome （APS） . Anti-β2GPI/β2GPI complex can bind to the surface membrane ofmonocytes and endothelial cells, promoting tissue factor （TF） activity on these cells, and thus increasing the risk of thrombosis.展开更多
基金Acknowledgments This work was supported by grants from National Natural Science Foundation of China （No.30370602 and 30670907） to Hong Zhou, We thank Dr, Monroe DM and Dr. Roubey RAS for providing factor VIIa and monoclonal anti-β2GPI antibody.
文摘Dear Editor： Growing evidence demonstrates that β2-glycoprotein Ⅰ （β2GPI） is the key target for antiphospholipid antibodies which are closely associated with thrombotic events in antiphospholipid syndrome （APS） . Anti-β2GPI/β2GPI complex can bind to the surface membrane ofmonocytes and endothelial cells, promoting tissue factor （TF） activity on these cells, and thus increasing the risk of thrombosis.
